# Aehr Test Systems share price today (Aehr Test Systems, Inc., AEHR)

> Aehr Test Systems, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AEHR · Technology · Semiconductor Equipment & Materials · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/aehr

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: $60.84 (+148.5% in a year)
- P/E: 39.9× (higher than 59% of the last 3.6 years)
- Revenue (May 2026): $18.8 M (+33.7% on a year ago)
- Profit (May 2026): $1.4 M
- Operating margin: −6.4% (+6.7 points on a year ago)
- ROE: −3%, FY26
- ROIC: −12.7%, against a 23.3% cost of capital: −36.0 points

The main question: profits are rising, but only 23% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Aehr Test Systems share price today? Aehr Test Systems, Inc.'s share price was $60.84 at the close on 4 November 2026. It has been moving sideways for 4 weeks. That is 18.7% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 4 weeks running. In the last 52 weeks it traded between $20 and $134, and at that close it sat 36% of the way up from that low. Over the last 10 years the share price moved +3,800% while the S&P 500 moved +261%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Aehr Test Systems pay? Aehr Test Systems, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Aehr Test Systems on? Aehr Test Systems is on one of our US lists: US tech stocks. [US tech stocks](https://www.sectoralpha.in/us-tech-stocks)

## Is Aehr Test Systems profitable? Aehr Test Systems, Inc. earned $1.4 M of net profit in the May 2026 quarter. The full FY26 year was a loss of $7.1 M. That is 7.4% of the quarter's revenue. The same quarter a year earlier lost $2.9 M. 7 of the last 12 reported quarters were loss-making. ## How much revenue does Aehr Test Systems make, and is it growing? Aehr Test Systems, Inc. reported $18.8 M of revenue in the May 2026 quarter, +33.7% on the same quarter a year earlier. Over 5 years it has grown 24.7% a year on average. The last full year, FY26, came in at $50.0 M. The last four reported quarters add to $50.0 M. FY26 revenue was $50.0 M, −15.2% on the year before. Recent pace: the last four quarters grew −13.2% on average, against 24.7% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −15.2%, against −13.1% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Aehr Test Systems keep? Aehr Test Systems, Inc.'s operating margin was −6.4% in the May 2026 quarter, 6.7 percentage points higher than the same quarter a year ago. Across 6 years it has been between −28.3% and 20.6%. The latest quarter is within that range. Why the margin moved: operating margin changed +6.7 percentage points on the year while gross margin changed +12.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Aehr Test Systems' profit turning into cash? Over the last 3 years, 23% of Aehr Test Systems, Inc.'s reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used $3.3 M of cash, against −$7.1 M of profit. After $2.1 M of spending on assets, free cash was −$5.4 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Aehr Test Systems' cash go? Aehr Test Systems, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $7.8 M on assets over the last 3 years. Averaged over those years that is 5.2% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $7.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Aehr Test Systems' P/E ratio, and how does it compare with its own history? Aehr Test Systems, Inc.'s P/E is 39.9×, in the middle of its own history: higher than 59% of past readings. Its usual P/E (the middle reading) is 33.1×, over 3.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved +35.4% a year; about +32.7% a year came from earnings growth and about +2.7 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Aehr Test Systems business getting better or worse? Aehr Test Systems, Inc.'s business is getting worse. Revenue, profit and EPS growth are shrinking: revenue growth is −15.2% in the latest quarter, against +34.1% at its best in 12 quarters, with ROCE steady at -7.8%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Aehr Test Systems earn on its capital? Aehr Test Systems, Inc. earned a ROE of −3% in FY26. That is up from a low of −18% in FY21. Its return on capital used (ROIC) is 36.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −14.3% net margin and 0.20× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −14.3% net margin × 0.20× asset turnover × 1.12× leverage (assets divided by equity) ≈ −3.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −12.7% − 23.3% = −36.0 percentage points. The 23.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Aehr Test Systems have too much debt? Aehr Test Systems, Inc. has total debt of $9.9 M against shareholder equity of $220 M as of May 2026, so its debt is 0.05× its equity, which is very little. Year by year, that ratio went from 0.42 in FY21 to 0.05 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Aehr Test Systems shareholding pattern? 18.0% of Aehr Test Systems, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 2.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Aehr Test Systems from balance-sheet trouble? For Aehr Test Systems, Inc., the Z-score is 23.98. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 23.98 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Aehr Test Systems rank in its industry? 40.6 out of 100, rank 20 of 29 in Semiconductor Equipment & Materials, with 64% of the evidence available. Aehr Test Systems, Inc. scores 40.6 out of 100 against the 29 companies it is compared with in Semiconductor Equipment & Materials, ranking 20. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 13.2 + 4.8 + 11.5 + 11.1 = 40.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Aehr Test Systems compared with? Aehr Test Systems ranks 20 of 29 Semiconductor Equipment & Materials companies on the 4-Factor Sector Score, with 40.6 out of 100. 1. [ASML Holding N.V.](https://www.sectoralpha.in/us/stocks/asml) ASML · quiet · Most evidence points up · 85% evidence 76.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/35 · Revenue 22.5% · Profit 42.4% · Operating margin change 11.6 points · 95% evidence Capital efficiency 21.0/25 · ROCE 44.7% · Operating margin 44.4% · 76% evidence Valuation 13.2/20 · P/E 43.3× · PEG 0.97 · 65% evidence Relative strength 16.4/20 · Lead over its industry 7.9% · Lead over S&P 500 -6.1% · 1 year 47.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.6 + 21 + 13.2 + 16.4 = 76.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Lam Research Corporation](https://www.sectoralpha.in/us/stocks/lrcx) LRCX · quiet · Most evidence points up · 85% evidence 71.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.2/35 · Revenue 33.4% · Profit 45.4% · Operating margin change 5.6 points · 95% evidence Capital efficiency 21.4/25 · ROCE 50.7% · Operating margin 40% · 76% evidence Valuation 13.0/20 · P/E 46.7× · PEG 0.97 · 65% evidence Relative strength 8.1/20 · Lead over its industry -6.2% · Lead over S&P 500 -20% · 1 year 39% · 100% evidence · 0 of 12 weeks ahead Exact sum: 29.2 + 21.4 + 13 + 8.1 = 71.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Teradyne, Inc.](https://www.sectoralpha.in/us/stocks/ter) TER · losing its lead · Most evidence points up · 81% evidence 67.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 57.8% · Profit 100% · Operating margin change 18.9 points · 83% evidence Capital efficiency 20.4/25 · ROCE 36.7% · Operating margin 33.2% · 76% evidence Valuation 11.8/20 · P/E 59.5× · PEG 1.03 · 65% evidence Relative strength 4.5/20 · Lead over its industry -12.2% · Lead over S&P 500 -25.4% · 1 year 37.8% · 100% evidence · 2 of 12 weeks ahead Exact sum: 31 + 20.4 + 11.8 + 4.5 = 67.7 · What this means: Earnings are strong; relative strength in its sector is -12.2% and the one-year return is 37.8%. 4. [KLA Corporation](https://www.sectoralpha.in/us/stocks/klac) KLAC · quiet · Evidence leans up · 85% evidence 63.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue 15.8% · Profit 24.1% · Operating margin change 3.3 points · 95% evidence Capital efficiency 21.1/25 · ROCE 44.7% · Operating margin 45% · 76% evidence Valuation 8.7/20 · P/E 48.4× · PEG 1.91 · 65% evidence Relative strength 11.0/20 · Lead over its industry -3.9% · Lead over S&P 500 -17.2% · 1 year 25.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 22.3 + 21.1 + 8.7 + 11 = 63.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kulicke and Soffa Industries, Inc.](https://www.sectoralpha.in/us/stocks/klic) KLIC · quiet · Evidence leans up · 64% evidence 59.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 44.8% · Profit 100% · Operating margin change 20 points · 62% evidence Capital efficiency 14.3/25 · ROCE 12.5% · Operating margin 20.7% · 76% evidence Valuation 10.1/20 · P/E 54.9× · PEG n/a · 15% evidence Relative strength 11.4/20 · Lead over its industry -2.4% · Lead over S&P 500 -17.8% · 1 year 78.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 24.1 + 14.3 + 10.1 + 11.4 = 59.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Applied Materials, Inc.](https://www.sectoralpha.in/us/stocks/amat) AMAT · quiet · Evidence leans up · 85% evidence 57.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.8/35 · Revenue 7.8% · Profit 35.6% · Operating margin change 3.1 points · 95% evidence Capital efficiency 20.1/25 · ROCE 29% · Operating margin 33.7% · 76% evidence Valuation 11.4/20 · P/E 45.9× · PEG 1.21 · 65% evidence Relative strength 9.6/20 · Lead over its industry 0.5% · Lead over S&P 500 -14.5% · 1 year 60.5% · 100% evidence · 1 of 12 weeks ahead Exact sum: 16.8 + 20.1 + 11.4 + 9.6 = 57.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Cohu, Inc.](https://www.sectoralpha.in/us/stocks/cohu) COHU · losing its lead · Evidence leans up · 64% evidence 55.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.4/35 · Revenue 32.5% · Profit n/a · Operating margin change 15.4 points · 62% evidence Capital efficiency 4.8/25 · ROCE -2.9% · Operating margin 0.6% · 76% evidence Valuation 10.8/20 · P/E 27.1× · PEG n/a · 15% evidence Relative strength 16.7/20 · Lead over its industry 16.4% · Lead over S&P 500 -2.3% · 1 year 83.8% · 100% evidence · 3 of 12 weeks ahead Exact sum: 23.4 + 4.8 + 10.8 + 16.7 = 55.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [FormFactor, Inc.](https://www.sectoralpha.in/us/stocks/form) FORM · losing its lead · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.3/35 · Revenue 18.1% · Profit 100% · Operating margin change 17.8 points · 83% evidence Capital efficiency 15.8/25 · ROCE 12.7% · Operating margin 24.1% · 76% evidence Valuation 4.6/20 · P/E 88.3× · PEG 4.6 · 65% evidence Relative strength 6.5/20 · Lead over its industry -6.9% · Lead over S&P 500 -21.7% · 1 year 63.1% · 100% evidence · 2 of 12 weeks ahead Exact sum: 28.3 + 15.8 + 4.6 + 6.5 = 55.2 · What this means: Earnings are strong; relative strength in its sector is -6.9% and the one-year return is 63.1%. 9. [Amkor Technology, Inc.](https://www.sectoralpha.in/us/stocks/amkr) AMKR · quiet · Evidence leans up · 81% evidence 54.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.8/35 · Revenue 17.9% · Profit 82.9% · Operating margin change 4.4 points · 83% evidence Capital efficiency 12.4/25 · ROCE 8.5% · Operating margin 10.5% · 76% evidence Valuation 14.8/20 · P/E 38.5× · PEG 0.68 · 65% evidence Relative strength 2.7/20 · Lead over its industry -27.2% · Lead over S&P 500 -37.5% · 1 year 2.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 24.8 + 12.4 + 14.8 + 2.7 = 54.7 · What this means: Earnings are strong; relative strength in its sector is -27.2% and the one-year return is 2.5%. 10. [Photronics, Inc.](https://www.sectoralpha.in/us/stocks/plab) PLAB · quiet · Evidence leans up · 85% evidence 53.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 1.3% · Profit 51.4% · Operating margin change -1.8 points · 95% evidence Capital efficiency 15.2/25 · ROCE 10.9% · Operating margin 21.1% · 76% evidence Valuation 16.0/20 · P/E 10.8× · PEG 0.43 · 65% evidence Relative strength 8.5/20 · Lead over its industry -14.9% · Lead over S&P 500 -24.7% · 1 year 26.1% · 100% evidence · 1 of 12 weeks ahead Exact sum: 14.2 + 15.2 + 16 + 8.5 = 53.9 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 11. [Qnity Electronics, Inc.](https://www.sectoralpha.in/us/stocks/q) Q · quiet · Evidence leans up · 65% evidence 53.2 out of 100 Growth Capital Valuation Relative
12. [Entegris, Inc.](https://www.sectoralpha.in/us/stocks/entg) ENTG · losing its lead · Evidence leans up · 81% evidence 52.9 out of 100 Growth Capital Valuation Relative
13. InTest Corporation INTT · turning · Evidence leans up · 64% evidence 52.5 out of 100 Growth Capital Valuation Relative
14. [AXT, Inc.](https://www.sectoralpha.in/us/stocks/axti) AXTI · losing its lead · Evidence leans up · 64% evidence 51.0 out of 100 Growth Capital Valuation Relative
15. [IPG Photonics Corporation](https://www.sectoralpha.in/us/stocks/ipgp) IPGP · basing · Evidence leans down · 74% evidence 49.3 out of 100 Growth Capital Valuation Relative
16. [Ambarella, Inc.](https://www.sectoralpha.in/us/stocks/amba) AMBA · quiet · Evidence leans down · 67% evidence 49.3 out of 100 Growth Capital Valuation Relative
17. [Amtech Systems, Inc.](https://www.sectoralpha.in/us/stocks/asys) ASYS · quiet · Evidence leans down · 64% evidence 44.8 out of 100 Growth Capital Valuation Relative
18. [Nova Ltd.](https://www.sectoralpha.in/us/stocks/nvmi) NVMI · basing · Evidence leans down · 81% evidence 44.4 out of 100 Growth Capital Valuation Relative
19. [Onto Innovation Inc.](https://www.sectoralpha.in/us/stocks/onto) ONTO · quiet · Too little evidence to rank firmly · 56% evidence 41.0 out of 100 Growth Capital Valuation Relative
20. Aehr Test Systems, Inc. this page AEHR · losing its lead · Evidence leans down · 64% evidence 40.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.2/35 · Revenue -13.8% · Profit n/a · Operating margin change 6.7 points · 62% evidence Capital efficiency 4.8/25 · ROCE -6.2% · Operating margin -6.4% · 76% evidence Valuation 11.5/20 · P/E -407.5× · PEG n/a · 15% evidence Relative strength 11.1/20 · Lead over its industry 13.9% · Lead over S&P 500 -9.2% · 1 year 148.5% · 100% evidence · 3 of 12 weeks ahead Exact sum: 13.2 + 4.8 + 11.5 + 11.1 = 40.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 21. [ACM Research, Inc.](https://www.sectoralpha.in/us/stocks/acmr) ACMR · quiet · Evidence leans down · 81% evidence 39.5 out of 100 Growth Capital Valuation Relative
22. [Camtek Ltd.](https://www.sectoralpha.in/us/stocks/camt) CAMT · quiet · Evidence leans down · 81% evidence 38.5 out of 100 Growth Capital Valuation Relative
23. [Veeco Instruments Inc.](https://www.sectoralpha.in/us/stocks/veco) VECO · quiet · Evidence leans down · 81% evidence 37.7 out of 100 Growth Capital Valuation Relative
24. [Axcelis Technologies, Inc.](https://www.sectoralpha.in/us/stocks/acls) ACLS · quiet · Evidence leans down · 81% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [Ichor Holdings, Ltd.](https://www.sectoralpha.in/us/stocks/ichr) ICHR · quiet · Most evidence points down · 64% evidence 34.7 out of 100 Growth Capital Valuation Relative
26. [Daqo New Energy Corp.](https://www.sectoralpha.in/us/stocks/dq) DQ · quiet · Most evidence points down · 64% evidence 34.2 out of 100 Growth Capital Valuation Relative
27. [Ultra Clean Holdings, Inc.](https://www.sectoralpha.in/us/stocks/uctt) UCTT · quiet · Most evidence points down · 64% evidence 34.1 out of 100 Growth Capital Valuation Relative
28. Trio-Tech International TRT · Too little evidence to rank firmly · 0% evidence 50.0 out of 100 Growth Capital Valuation Relative
29. Atomera Incorporated ATOM · quiet · Too little evidence to rank firmly · 49% evidence 38.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Semiconductor Equipment & Materials](https://www.sectoralpha.in/us/sectors/semiconductor-equipment-materials), all 29 compared on one page. ## Which companies are close to Aehr Test Systems in size? Aehr Test Systems is the 22nd largest of 26 Semiconductor Equipment & Materials companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Veeco Instruments Inc., Ultra Clean Holdings, Inc. and Cohu, Inc. Just below it: Photronics, Inc., Ichor Holdings and Daqo New Energy Corp. ### Semiconductor Equipment & Materials companies close in size

1. [Veeco Instruments Inc.](https://www.sectoralpha.in/us/stocks/veco) $2.2 billion
2. [Ultra Clean Holdings, Inc.](https://www.sectoralpha.in/us/stocks/uctt) $2.1 billion
3. [Cohu, Inc.](https://www.sectoralpha.in/us/stocks/cohu) $2.1 billion
4. Aehr Test Systems, Inc. $2 billion
5. [Photronics, Inc.](https://www.sectoralpha.in/us/stocks/plab) $1.6 billion
6. [Ichor Holdings, Ltd.](https://www.sectoralpha.in/us/stocks/ichr) $1.3 billion
7. [Daqo New Energy Corp.](https://www.sectoralpha.in/us/stocks/dq) $813 million

[All 26 Semiconductor Equipment & Materials companies, largest first](https://www.sectoralpha.in/us/sectors/semiconductor-equipment-materials#all-companies)

### Companies close in size in other industries

1. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) $2 billion · Medical Devices
2. [Vir Biotechnology, Inc.](https://www.sectoralpha.in/us/stocks/vir) $2 billion · Biotechnology
3. Aehr Test Systems, Inc. $2 billion
4. [Innospec Inc.](https://www.sectoralpha.in/us/stocks/iosp) $2 billion · Specialty Chemicals
5. [Sonos, Inc.](https://www.sectoralpha.in/us/stocks/sono) $2 billion · Consumer Electronics

## What else do people ask about Aehr Test Systems? ### What is Aehr Test Systems's stock price today? Aehr Test Systems, Inc.'s stock price is $60.84, +148.5% over the past year. The whole company is worth $2.0 B on the market. In the last 52 weeks it traded between $20 to $134; today it is 36% of the way up from the low, 18.7% below its 200-day average (as of 4 November 2026). ### What were Aehr Test Systems's latest quarterly results? Aehr Test Systems, Inc. reported revenue of $18.8 M and net profit of $1.4 M for the May 2026 quarter. Earnings per share were $0.04. The operating margin was −6.4%, 6.7 percentage points higher than a year earlier (as of 4 November 2026). ### What is Aehr Test Systems's market cap? Aehr Test Systems, Inc.'s market capitalisation is $2.0 B at a stock price of $60.84. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Aehr Test Systems performing? Aehr Test Systems, Inc.'s share price has been moving sideways for 4 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 4 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Aehr Test Systems's stock price go up? This page does not forecast Aehr Test Systems, Inc.'s stock price. What it shows instead: the stock price is $60.84, and it has been moving sideways for 4 weeks. Its P/E of 39.9× is higher than 59% of its own last 4 years (as of 4 November 2026). ### Where is Aehr Test Systems in its business cycle? Aehr Test Systems, Inc.'s FY26 operating margin was −28.3%, against a 6-year range of −28.3% to 20.6%: the low end of its own range, which is often where recoveries start. The latest quarter was −6.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Aehr Test Systems story? The main question: profits are rising, but only 23% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Aehr Test Systems a stock worth studying right now? What the numbers show: Aehr Test Systems, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- US tech stocks: https://www.sectoralpha.in/us-tech-stocks

This is research, not advice. We’re not SEBI-registered.